retatrutide phase 2 results obesity nejm 2023

retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide in adults with obesity

Name: retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide in adults with obesity
Brand: www.wloczykij.org
SKU: 8242444969
Price: 21.96 USD
Availability: InStock
Rating: 4.3978 (20 reviews)

SKU: 8242444969

4.4

EUR21.96 EUR71.96

Pay in 4 interest-free payments of $5.49 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 9 - Aug 14

Description

Patients with high A1c often achieve only about half the weight loss predicted for non-diabetics

No medication replaces lifestyle

Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release

This study, which focused on adults with Type 2 diabetes, showed that retatrutide achieved an average A1C reduction of up to 2.0% and significant body weight loss in just 40 weeks